Revolution Medicines (RVMD) Income towards Parent Company (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Income towards Parent Company of -$453.8 million for Q1 2026, down 112.64% year-over-year from $3.6 billion in Q1 2025, and down 159.21% quarter-over-quarter from $766.4 million in Q4 2025.
Revolution Medicines (RVMD) Income towards Parent Company (2019 - 2026) Analysis & Trends
Revolution Medicines' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 112.64% year-over-year to -$453.8 million; the TTM figure through Mar 2026 stood at -$240.4 million (up 65.53% YoY), while the FY2024 annual figure was -$600.0 million, down 36.31% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$453.8 million, down from $766.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was $766.4 million in Q4 2025, with the low at -$453.8 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$116.0 million (2024), against an average of -$102.5 million.
- The sharpest annual moves came in 2023 and 2025: Income towards Parent Company tumbled 192.58% in 2023, then jumped 494.0% in 2025.
- Revolution Medicines' Income towards Parent Company stood at -$56.5 million in 2022, then plunged by 192.58% to -$165.4 million in 2023, then retreated by 17.62% to -$194.5 million in 2024, then surged by 494.0% to $766.4 million in 2025, then slumped by 159.21% to -$453.8 million in 2026.
- Business Quant data shows RVMD's Income towards Parent Company at -$453.8 million in Q1 2026, $766.4 million in Q4 2025, and -$305.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -644.37 Mn |
| Mar 31, 2026 | -453.82 Mn |
| Dec 31, 2025 | 766.41 Mn |
| Sep 30, 2025 | -305.21 Mn |
| Jun 30, 2025 | -247.79 Mn |
| Mar 31, 2025 | -213.42 Mn |
| Dec 31, 2024 | -194.52 Mn |
| Sep 30, 2024 | -156.29 Mn |
| Jun 30, 2024 | -133.23 Mn |
| Mar 31, 2024 | -116.00 Mn |
| Dec 31, 2023 | -165.39 Mn |
| Sep 30, 2023 | -108.43 Mn |
| Jun 30, 2023 | -98.30 Mn |
| Mar 31, 2023 | -68.10 Mn |
| Dec 31, 2022 | -56.53 Mn |
| Sep 30, 2022 | -73.33 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -57.65 Mn |
| Dec 31, 2021 | -52.68 Mn |
| Sep 30, 2021 | -52.94 Mn |